Zacks Research Has Negative Outlook of ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Zacks Research cut their FY2026 earnings per share (EPS) estimates for shares of Achieve Life Sciences in a research note issued to investors on Tuesday, March 24th. Zacks Research analyst J. Vandermosten now forecasts that the biopharmaceutical company will post earnings per share of ($1.40) for the year, down from their previous estimate of ($1.07). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($0.65) EPS.

Several other equities analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Achieve Life Sciences in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Achieve Life Sciences Price Performance

Achieve Life Sciences stock opened at $2.65 on Friday. The business has a 50 day simple moving average of $4.31 and a 200 day simple moving average of $4.29. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.39 and a quick ratio of 5.14. The company has a market capitalization of $141.07 million, a PE ratio of -2.04 and a beta of 1.81. Achieve Life Sciences has a one year low of $1.84 and a one year high of $6.03.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01).

Hedge Funds Weigh In On Achieve Life Sciences

A number of large investors have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in shares of Achieve Life Sciences in the first quarter valued at approximately $32,000. Next Capital Management LLC bought a new position in Achieve Life Sciences in the 3rd quarter worth approximately $51,000. Sender Co & Partners Inc. acquired a new position in Achieve Life Sciences during the 2nd quarter worth $56,000. OneDigital Investment Advisors LLC bought a new position in Achieve Life Sciences in the 3rd quarter valued at $63,000. Finally, Magnolia Capital Advisors LLC bought a new position in Achieve Life Sciences in the 4th quarter valued at $64,000. 33.52% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Achieve Life Sciences

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $12 target while materially boosting long‑range EPS forecasts (FY2029 and FY2030 upgrades), signaling confidence in ACHV’s longer‑term commercial potential. Achieve Life Sciences (NASDAQ:ACHV) Earns Buy Rating from HC Wainwright
• Positive Sentiment: A peer‑reviewed publication linked cytisinicline’s receptor profile to low nausea and favorable tolerability, a clinical differentiator that could support uptake if approved. Publication in Nicotine & Tobacco Research
• Positive Sentiment: Analysts and commentators are highlighting the upcoming PDUFA (June 20, 2026) and planned Phase 3 vaping cessation trial (ORCA‑V2 in 1H 2026) as major value catalysts toward a possible 1H‑2027 commercial launch if approved. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA…
• Positive Sentiment: Unusually large retail/institutional activity in call options suggests speculative bullish positioning ahead of the PDUFA and other near‑term catalysts. Investors Purchase Large Volume of Call Options on Achieve Life Sciences
• Neutral Sentiment: HC Wainwright also updated quarter‑by‑quarter 2026 EPS estimates (small quarterly losses expected) while keeping the Buy stance — important for modeling near‑term cash needs but not a directional change to the thesis. MarketBeat ACHV coverage
• Neutral Sentiment: The company’s Q4 2025 transcript and summary show a modest EPS miss and operational detail; useful for context on execution but not a game‑changer versus the upcoming FDA decision. Q4 2025 earnings call transcript Q4 2025 Earnings Call Summary
• Negative Sentiment: Mixed analyst revisions include downgrades to mid‑term EPS (HC Wainwright trimmed FY2027 and FY2028; Zacks cut FY2026/FY2027), which raises uncertainty on near‑term profitability and could pressure the stock ahead of the PDUFA. Market analyst estimate changes

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.